Projects

A $100,000 equity investment listed on CerebrumDAO's dashboard. Acta Pharmaceuticals is a clinical-stage biopharmaceutical company running a Phase 1 trial of an investigational oral compound, GSM-779690T, for Alzheimer's disease. Unlike CerebrumDAO's tokenized IP-NFT deals, later-stage equity investments made without an IP-NFT are not given individual project pages, which is why this one has no dedicated page on cerebrumdao.com.

AT-001, an oral small molecule (an NAC-amide/NACA derivative) that crosses the blood-brain barrier to disrupt amyloid plaques, targeting Alzheimer's and hereditary cystatin C amyloid angiopathy (HCCAA).

A protein-protein interaction inhibitor targeting the DRP1-FIS1 pathway to block pathological mitochondrial fission, aimed at age-related and neurodegenerative disease.

Testing galectin-3 inhibitors to reduce neuroinflammation in Alzheimer's mouse models, with a stated focus on peripheral (non-CNS-penetrant) indications.

A patent-protected brain-health dietary supplement combining a cat's-claw extract (PTI-00703®) and an oolong-tea extract (MemorTea®), aimed at memory loss and cognitive decline.

Improves the accuracy of protein synthesis (translation fidelity) to prevent the misfolding and aggregation implicated in neurodegenerative disease, particularly Alzheimer's.

A small-molecule positive allosteric modulator of SK (small-conductance calcium-activated potassium) channels, targeting spinocerebellar ataxia type 2 and essential tremor.

A neuroscience-based mobile app that builds brain-healthy habits through daily activities ("quests") targeting focus, stress, sleep, and productivity, with longitudinal cognitive-metric tracking.